Compare Wegovy® pricing

Wegovy® Pen

Weekly injection
Semaglutide
GLP-1
Prescription required
Wegovy® Pen clinical trials showed
~21% average weight loss at highest dose, 86% lost more than 5% of body weight.
More on Wegovy®
GET STARTED

Wegovy® Pill

Daily pill
Semaglutide
GLP-1
Prescription required
Wegovy® Pill clinical trials showed
~14% average weight loss, 76% lost more than 5% of body weight
More on Wegovy®
GET STARTED

See if medication is right for you

knownwell visits covered by insurance
97% of knownwell patients keep weight off after two years
Virtual & in-person visits, with the same clinician every time
GET STARTED WITH KNOWNWELL

Compare Zepbound® pricing

Zepbound® QwikPen

Weekly injection
Tirzepatide
GIP / GLP-1
Prescription required

Zepbound® Vial

Daily pill
Tirzepatide
GIP / GLP-1
Prescription required

Zepbound® Pen

Daily pill
Tirzepatide
GIP / GLP-1
Prescription required

Zepbound clinical trials showed

~21% average weight loss, 91% lost more than 5% of body weight
More on Zepbound®
GET STARTED

Ozempic® pricing

Ozempic®

Weekly injection
Semaglutide
GLP-1
Prescription required
Diabetes medication
Ozempic® clinical trials
~5–6% average weight loss, ~50% lost more than 5% of body weight
More on Ozempic®
GET STARTED

See if medication is right for you

GET STARTED WITH KNOWNWELL

Get bias-free weight management with knownwell

Experts in obesity medicine

Comprehensive, empathetic care from clinicians who specialize in weight management

In-network with insurance

We work with major insurance plans to help make your care and prescription as affordable as possible

Prior authorization support

Our dedicated team helps get your Ozempic® prescription covered — so you're not navigating coverage alone

In-person & virtual availability

Available via telehealth nationwide, with in-person clinics in select cities

Choosing the right option with confidence

When choosing a weight-management medication, clinicians look at several key factors:
We're here to help
Looking at your overall health picture

Ozempic® is a GLP-1 receptor agonist. It mimics GLP-1, a naturally occurring hormone released after you eat that helps regulate blood sugar, appetite, and digestion.

By activating GLP-1 receptors, Ozempic® works to increase insulin secretion when blood sugar is elevated, reduce glucagon (a hormone that raises blood sugar), slow the rate at which food leaves the stomach, and reduce hunger signals in the brain.

Thinking about your health goals

By working with these natural hormone signals, the medication helps bring blood sugar levels into balance while also reducing appetite and increasing feelings of fullness, making it easier to eat in alignment with your health goals.

Over time, people using Ozempic® as part of a broader care plan often see improvements in both blood sugar control and body weight.

‍

Making sure it fits your budget
  • Reduced hunger and fewer cravings between meals
  • Feeling satisfied sooner and for longer after eating
  • More stable blood sugar levels throughout the day
  • Gradual, sustained weight reduction over time
Considering how your body may react
  • Reduced hunger and fewer cravings between meals
  • Feeling satisfied sooner and for longer after eating
  • More stable blood sugar levels throughout the day
  • Gradual, sustained weight reduction over time
Finding what works best for your lifestyle
  • Reduced hunger and fewer cravings between meals
  • Feeling satisfied sooner and for longer after eating
  • More stable blood sugar levels throughout the day
  • Gradual, sustained weight reduction over time

Disclaimers

In the SUSTAIN 7 clinical trial, those taking semaglutide 1 mg once weekly reduced their HbA1c by an average of 1.8%, compared to 1.4% with dulaglutide 1.5 mg. Individual results vary.

Sources

1.
Alzahrani, A. M., Alshobragi, G. A., Alshehri, A. M., et al. (2025). Molecular pharmacology of glucagon-like peptide 1-based therapies in the management of type two diabetes mellitus and obesity. Integrated Pharmacy Research and Practice, 14, 59-72. doi:10.2147/IPRP.S503501. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11987703/
2.
Davy, B. M. (2025). Water intake, hydration, and weight management. Physiology & Behavior, 33(7), 1199-1200. doi:10.1002/oby.24177. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40374025/
3.
Dhamija, P., Bhatt, S. P. (2022). Semaglutide, a glucagon-like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Cardiovascular Medicine, 23(1), 1-14. doi:10.31083/j.rcm2301018. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8736331/
See all
4.
Gadde, K. M., Allison, D. B., Ryan, D. H., et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). The Lancet, 377(9774), 1341-1352. Retrieved from https://hcp.qsymia.com/efficacy-and-safety/study-conquer/
5.
Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613-626. doi:10.1016/S0140-6736(23)01200-X. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext
6.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. doi:10.1056/NEJMoa2206038. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
7.
Kommu, S., Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved on Mar. 9, 2026, from https://www.ncbi.nlm.nih.gov/books/NBK603723/
8.
Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine, 375(19), 1834-1844. doi:10.1056/NEJMoa1607141. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
9.
Mozaffarian, D., Agarwal, M., Aggarwal, M., et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity. American Journal of Lifestyle Medicine, 19(3). doi:10.1177/15598276251344827. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/
10.
Novo Nordisk Inc. FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Retrived from https://www.ozempic.com/content/dam/diabetes-patient/ozempic/pdfs/Ozempic_CKD_sNDA_Press_Release_January_28_2025.pdf
11.
Novo Nordisk Inc. Ozempic® cost and coverage resources. Retrieved from https://www.novomedlink.com/diabetes/products/treatments/ozempic/resources/cost-and-coverage.html
12.
Novo Nordisk Inc. Ozempic® list price information. Retrieved from https://www.novocare.com/diabetes/products/ozempic/explaining-list-price.html
13.
Novo Nordisk Inc. Ozempic® savings card program terms. Retrieved from https://www.novocare.com/eligibility/diabetes-savings-card.html
14.
Novo Nordisk Inc. Ozempic® savings offer. Retrieved from https://www.novocare.com/diabetes/products/ozempic/savings-offer.html
15.
Perkovic, V., Tuttle, K. R., Rossing, P., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine, 391(2), 109-121. doi:10.1056/NEJMoa2403347. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2403347
16.
Pratley, R. E., Aroda, V. R., Lingvay, I., et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology, 6(4), 275-286. doi:10.1016/S2213-8587(18)30024-X. Retrieved from https://pubmed.ncbi.nlm.nih.gov/29397376/
17.
U.S. Food and Drug Administration. (2025). OZEMPIC (semaglutide) injection, for subcutaneous use: Highlights of prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
18.
Wadden, T. A., Foreyt, J. P., Foster, G. D., et al. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity (Silver Spring), 19(1), 110-120. doi:10.1038/oby.2010.147. Retrieved from https://pubmed.ncbi.nlm.nih.gov/20559296/
19.
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11), 1077-1087. doi:10.1056/NEJMoa2500969. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2500969
20.
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. doi:10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

Every body tells a story. 
Let yours be knownwell.

We provide comprehensive, patient-centered, and expert-led care, in which you and your whole body are treated compassionately.
BOOK FIRST VISIT
RESOURCES
© 2026 knownwell – All Rights Reserved.